Publish date: February 28, 2019 By Sharon Worcester The high cost of chimeric antigen receptor (CAR) T-cell therapy largely limits its use to the sickest patients and prohibits experimentation in “less-diseased” populations, outcomes data suggest.
By Duane Schulthess - 26 December 2018
It’s odd that a city like Brussels managed to carve itself out a niche as one of the major political centres of the world. The medieval site of a notoriously typhus infested bog, one of the main streets in downtown, ‘Rue du Marais’, literally means, “Street of the Swamp” and the name of the city itself comes from the old Flemish word Broekzele, which roughly translates to ‘settlement in the swamp.’ So, when one talks politically of draining the swamp, at least in Brussels, it carries a literal interpretation that is often distant from the current political climate in DC.
What goes without question is that both Brussels and DC are currently heaving under waves of increasing populist threats to drain political swamps. With the Brexit referendum followed by the election of President Trump, we also now have the Yellow Vest protests in France coupled with a letter accusing President Macron of treason signed by a dozen French generals and a former Minister of Defense. There is an air of anger against political institutions on both sides of the Atlantic, and increasingly, the heated rhetoric is being pointed at the price of medicines.
Vital Transformation released its newest research at the European Health Forum Gastein on October 4th, 2018. Our project analysed 116 EU biotech start-ups from the period of 2001 – 2007 through September 21, 2018 from the UK, Netherlands, Belgium, and Spain. We focused on companies developing medicinal products for human consumption. In this work, we compared the impact of IPOs (stock market listings), private investors, and direct EU funding on their success or failure.
24th June 2018, Boston, USA
Duane Schulthess, Managing Director of Vital Transformation, and Luca Pani, former Director General of the Italian Medicine's Agency and currently a Faculty Member at the University of Miami, will run a 3 hour and 15 minute Short Course outlining how best to harness RWE to better understand the price, value, and impact of next generation therapies.
30th December, 2017
The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.
21st October, 2015
After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is
beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the
guidance of the European Medicines Agency in 2014.
9th March, 2015
A new report from the ABPI and Vermilion Life Sciences examines the challenges and changes needed for the UK to lead reengineering medicines development, and proposes a new methodology to achieve this.
3rd November, 2014
By Wendy L. Currie and Jonathan J.M. Seddon
One of the biggest health care challenges in the coming years is how technology can be used to improve health service delivery. With the steadily increasing average life expectancy across all of Europe expected to be over 80 by 2025 and 82.5 by 2050, new and improved processes need to be delivered to meet future health requirements.
29th October, 2014
A presentation by health care consultancy VitalTransformation shows that a fifth could be cut off clinical trial times and up to $300 million saved if databases were used for trial recruitment.
19th May, 2014
Abstract
Eroom’s Law is, literally, Moore’s law in reverse. The pharmaceutical sector invests $50 billion annually in research for new medicines but, “the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms”. Pharmaceutical companies have invested enormous sums in new molecular entities (NME) in the areas of unmet medical need identified by the World Health Organization (WHO), but the approval rates from phase I are only 7% for cardiovascular disease, dropping to 4% for Alzheimer’s disease.
